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Abstract: Since the first description in 1982, totally implanted venous access ports have 
 progressively improved patients’ quality of life and medical assistance when a medical condition 
requires the use of long-term venous access. Currently, they are part of the standard medical care 
for oncohematologic patients. However, apart from mechanical and thrombotic complications, 
there are also complications associated with biofilm development inside the catheters. These 
biofilms increase the cost of medical assistance and extend hospitalization. The most frequently 
involved micro-organisms in these infections are gram-positive cocci. Many efforts have been 
made to understand biofilm formation within the lumen catheters, and to resolve catheter-
related infection once it has been established. Apart from systemic antibiotic treatment, the use 
of local catheter treatment (ie, antibiotic lock technique) is widely employed. Many different 
antimicrobial options have been tested, with different outcomes, in clinical and in in vitro assays. 
The stability of antibiotic concentration in the lock solution once instilled inside the catheter 
lumen remains unresolved. To prevent infection, it is mandatory to perform hand hygiene before 
catheter insertion and manipulation, and to disinfect catheter hubs, connectors, and injection 
ports before accessing the catheter. At present, there are still unresolved questions regarding the 
best antimicrobial agent for catheter-related bloodstream infection treatment and the duration 
of concentration stability of the antibiotic solution within the lumen of the port.
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Introduction
The use of totally implanted venous access devices has become a routine procedure 
since it was first described in 1982, when the use of a novel system consisting of a 
silicone rubber catheter connected to a subcutaneously placed molded plastic injec-
tion port for administration of intra-arterial chemotherapy was reported.1 Ports have 
progressively improved patients’ quality of life and medical assistance when a medical 
condition requires the use of a long-term venous access for administration of blood 
products, fluids, chemotherapy, antibiotics, or total parenteral nutrition. Ports are also 
useful for blood sampling procedures. Currently, they are part of the standard medi-
cal care for oncohematologic patients. However, infection is a major problem when 
it develops.
As occurs with other medical devices, infections are associated with biofilm 
development. Measures taken to reduce the occurrence of catheter-related infections 
(CRI) are not always enough to avoid biofilm generation. In some cases, infections are 
aggressive or may turn persistent, threatening the patient’s life. These situations often 
require catheter removal and prolonged systemic antibiotic treatment, which can 
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deteriorate clinical condition of the patient and complicate 
medical assistance.
Long-term catheters
Central venous catheters (CVC) may be necessary for 
temporary or long-term use. Long-term catheters may be 
partially or totally indwelling, and can be placed through an 
open surgical or percutaneous approach. A venous catheter 
indwelling for more than 14 days is considered a long-term 
venous catheter.2
There are two types of long-term central venous 
 catheters: cuffed or tunneled catheters, and catheters that end 
in a subcutaneous reservoir. Ports are composed of two parts: 
a central injection chamber, called the reservoir, which is 
made of titanium steel and has a self-sealing silicone rubber 
membrane; and a silicone rubber outlet catheter, to which the 
reservoir is connected. The standard implantation technique 
places the catheter in the right infraclavicular space via 
skin incision.1,3 Reservoirs are located in a pocket created 
under the skin surface and fixed to the underlying muscle 
fascia. The outlet catheter leads through a subcutaneous 
tunnel into a central vein. The catheter tip is left near the 
junction of the superior vena cava with the right atrium. The 
access to the silicone septum is made using a Huber point 
needle that is placed through a percutaneous insertion. This 
needle preserves the integrity of the septum. Ports need 
only a monthly flush of heparin to avoid thrombotic 
complications.
Prevalence of venous catheter-related 
infections
In spite of the precautionary measures taken, such as skin 
cleaning using a 70% alcohol or 0.5% chlorhexidine solu-
tion, it is estimated that the number of bloodstream infections 
(BSI) related to intravascular devices (IVD) range between 
250,000 and 500,000 per year in the US.4
Data reported from the National Healthcare Safety 
Network indicate that rates of central line-associated BSI 
in long-term acute care hospitals are 1.25 events per 1,000 
device days (range, 0.0–5.96),5 but the trend of catheter-
related bloodstream infection (CRBSI) decreased during the 
past decade, as was pointed out in a 2010 report of infection 
control in intensive care units.5
Ports are preferred for pediatric and oncohematologic 
patients because of their simplicity when used by qualified 
health care professionals. However, the rate of port infection 
in this patient group ranges from 0.016 to 0.25/1,000 IVD 
days.3,4,6
Pathogenesis: bacterial biofilm 
development
As well as other infections related to almost every temporary 
or permanent medical implant, such as orthopedic prosthesis 
and cardiac and neurological devices,8 venous device infec-
tions are associated with biofilm development on the surface 
of the foreign body. Most of the infections originate from the 
skin microbiota surrounding the insertion site of the catheter. 
Micro-organisms reach the subcutaneous catheter tract at the 
moment of venous catheter implantation. This event is often 
related to external colonization of short-term catheters.2,9 For 
internal colonization of the catheter, the sources of micro-
organisms are the bloodstream, when transient bacteremia 
occurs, and catheter hubs’ handling. Catheter manipulation is 
implicated with intraluminal colonization of long-term cath-
eters.10,11 Repeated access to ports often leads to formation 
of intraluminal biofilm.4 It has been estimated that biofilms 
are associated with more than 70% of nosocomial infections, 
and that the treatment of these biofilm-related infections costs 
more than a billion dollars annually.12
The first descriptions of bacterial biofilms pertained to 
flowing-water systems, but it not was until the early 1980s 
when characterization of the bacterial glycocalyx and its 
inherent ability to form adherent microcolonies through cel-
lular adhesion became relevant in the pathogenesis of infec-
tious diseases. Since then, clinical reports have focused more 
frequently on infectious processes associated with medical 
device-associated biofilms.
The interaction between micro-organisms and synthetic 
material creates a complex structure known as biofilm; 
however, it is difficult to provide a unique definition due 
to the wide range of bacterial and host substances involved 
in the biofilm generation process. The first step in biofilm 
development is the attachment of bacterial cells to an 
artificial or native surface. Micro-organisms will form a 
community that will encase itself in a self-produced poly-
meric matrix.12,13 The physiological changes experienced by 
bacterial cells during transition from planktonic to attached 
state are complex. During this process, many different 
phenotypes of the same organism with distinct proteins 
expression can be  characterized.14 Attached bacteria begin 
to form microcolonies and secrete a polymeric matrix. This 
matrix is a hydrated polyanionic complex of exopolysac-
charides of bacterial origin, but can also be formed by 
proteins and DNA. As the polymeric matrix grow and 
matures, it builds a sophisticated system of water channels 
resembling a circulatory system for biofilm support. The 
fluid flow through the water channels is responsible for 
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oxygenation, nourishment, hydration, removal of metabolic 
waste products, and communication between bacterial cells 
(quorum sensing); but this flow is not uniform, providing 
different cellular microenvironments. Therefore, oxygen 
diffusion at the center of cellular microcolonies is limited13 
(Figure 1).
The composition and metabolism of biofilms may vary 
significantly depending on the involved micro-organism, the 
stage of maturity of bacterial cells, and the local and immune 
conditions of the host. This leads to multiple biofilm pheno-
types, even among different species.
The generation process of biofilm may start only a few 
hours after venous device access has been placed; however, 
clinical features related to a CVC infection may not be appar-
ent until days or weeks after a port has been used for medical 
care. As biofilm matures on the internal surface of a venous 
catheter, new bacterial populations are released to the blood-
stream, either by single releasing cells or by biofilm particles’ 
detachment. This process allows the micro-organisms to 
maintain an infection and reach new tissue surfaces, where 
they can generate new infectious processes.
Biofilm-related issues
Micro-organisms obtained from biofilm sessile cells from 
removed ports have the same minimal inhibitory concen-
tration (MIC) as the planktonic form of the bacterial cells 
obtained from positive blood cultures drawn when ports 
were placed.15 This finding confirms the protection granted 
to bacterial cells growing in biofilms, even when antibiotics 
reach concentrations 1,000 times over that needed to kill 
planktonic cells in the bloodstream.15,16
Biofilms are resistant to the immune system.  Therefore, 
complete clearance of biofilm is not possible by only the host 
immune system. Different mechanisms may be involved in 
giving the biofilm this kind of natural immunity, such as the 
inability of phagocyte cells to kill biofilm micro-organisms 
due to the poor penetration of reactive oxygen species into 
the biofilm.8
Biofilms are also resistant to antibiotic activity. Many 
factors are involved in this resistance, such as poor antibi-
otic penetration into the biofilm depths and the polymeric 
matrix of the biofilm structure. Both act at the same 
time as a barrier that might physically reduce antibiotic 
penetration and adsorb antimicrobials agents, reducing 
the drug available to interact with biofilm bacteria.12 
Other factors associated with antimicrobial resistance are 
directly related to the organisms growing into the biofilm, 
and their microenvironment and metabolic state.15 Bacte-
rial cells in the biofilm are physiologically different from 
their planktonic counterparts and express specific protec-
tive factors, such as antibiotic efflux pumps and enzymes 
capable of neutralizing antibiotic drugs.17 These bacterial 
cells may escape from the effect of antimicrobial agents. 
These cells are known as persisters, and even though they 
may not be resistant to the employed antibiotic, they do 
not grow.
Owing to the complex and heterogeneous nature of bio-
film, several mechanisms of resistance are triggered at the 
same time within a single community of micro-organisms.12 
The exposure of slowly reproducing bacteria to antibacterial 
drugs may trigger the generation of mechanisms of antibiotic 
resistance in the micro-organisms. This antibiotic resistance 
makes the treatment of infection and the eradication of 
colonized  prosthetic or native  tissue surfaces, a challenge 
for physicians,17 risking the patient’s life or, at best, causing 
the loss of the affected port.
Figure 1 Biofilm development.
Notes: I Planktonic bacteria; II Attachment of bacterial cells; III Bacterial cells form a biofilm using their pili and exopolysaccharide; IV Mature biofilm; V Release of micro-
organisms to the bloodstream.
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From biofilm generation to port 
complications
Port-related complications can be classified as mechanical or 
infectious. Although both types of complications may appear 
at any time after implantation, usually mechanical complica-
tions appear soon after implantation (around 0.40/1,000 IVD 
days6), while infection-related complications are most likely 
to appear later on.18
The micro-organisms most commonly implicated in 
CRBSI associated with percutaneously inserted, noncuffed 
catheters are coagulase-negative Staphylococcus (CoNS), 
Staphylococcus aureus, enteric gram-negative bacilli, 
Pseudomonas species, and Candida species.2,19 Gram-
positive cocci are responsible for around 65% of cases of 
catheter-related bacteremia (CRB),20,21 and are the most 
frequent gram-positive cocci involved in colonization and 
biofilm formation of intravenous devices.10 Staphylococcus 
aureus deserve a special mention because of the virulence of 
the pathogen and its ability to cause more serious complica-
tions that may risk patients’ lives.2
Clinical manifestations of CRBSI
CRI represent a wide spectrum of frequent and sometimes 
severe complications associated with the use of venous 
devices. The clinical scenarios include skin and soft tissue 
infections, subcutaneous pocket infection, tunnelitis, CRB, 
septic thrombophlebitis, infective endocarditis, metastatic 
septic dissemination such as septic pulmonary embolisms, 
osteomyelitis, spleen and liver abscesses, and in the worst 
cases, septic shock.
Diagnosis of CRBSI
CRBSI is diagnosed when no other detectable focus of infec-
tion, except the catheter, is identified. Clinical diagnosis 
is usually based on fever (.38°C), chills or hypotension, 
a tunneled venous catheter in use 48 hours prior to the 
development of infection, and a positive blood culture with 
isolation of the same micro-organism from the catheter and 
bloodstream. There is local purulence (with the same micro-
organism that is in blood cultures), increased warmth and 
induration extending at least 2 cm from the CVC insertion 
site, disappearance of signs of infection and a return to a 
normal temperature within 24 hours after catheter removal 
without antibiotic treatment, and a positive quantitative 
catheter culture, with isolation of the same micro-organism 
from the catheter and bloodstream.22 Diagnosis of CRBSI 
requires that the same micro-organism grow from at least one 
blood culture and from the culture of the catheter tip. In the 
case of less virulent micro-organisms, such as Micrococcus, 
Corynebacterium, and Bacillus species, at least two positive 
results of blood cultures on samples obtained from different 
sites are required.2
Risk factors for CRI are associated with the time of 
catheterization and handling of the venous catheter,3,11,21 the 
variables related to the type of tunneled catheter,4,21 catheter 
insertion technique,3,4 catheter placement,4 hematological 
malignancies,3,20,21 patient age,20 parenteral nutrition 
administration,19,23 immunosuppression,24 and prolonged 
neutropenia.6
Withdrawing the catheter removes the source of infection 
and enables microbiological analysis of the catheter, but the 
decision to remove a catheter should take into consideration 
at least three factors: the type of the catheter; the micro-
organism involved in the infection; and clinical status of 
the patient.25
Conservative diagnosis of CRB
There are two methods for in situ diagnosis of CRB: quantita-
tive culture of paired blood samples, and differential time to 
positivity of catheter blood sample compared to peripheral 
vein blood culture. Quantitative culture of paired blood 
samples looks for the correlation between a positive differen-
tial quantitative blood culture threefold greater than identical 
bacterial colony count in peripheral vein blood specimen.2 
This test is considered indicative of CRB with 77.8% sen-
sitivity, 100% specificity, and an overall accuracy of 91.7%. 
When it is not possible to obtain blood from peripheral vein 
puncture, or if the patient has a multiple lumen catheter, 
Infectious Diseases Society of America (IDSA) guidelines 
suggest that diagnosis of CRB can be assessed by isolation 
of $100 colony-forming units (CFU)/mL bacteria from 
a single quantitative blood culture drawn from one of the 
lumens of the catheter.2 For multiple lumen venous catheters, 
blood cultures should be drawn from all lumens in order to 
increase the sensitivity of a single blood culture sample.26 
Not sampling one of the lumens may result in a failure to 
diagnose CRB.27
In differential time to positivity of catheter blood 
sample compared to peripheral vein blood culture,2,28 
a cut-off differential time to positivity value of 120 minutes 
has 91% specificity and 94% sensitivity for the diagnosis 
of CRB.28
Diagnosis of CRB after catheter removal
The challenge is to solve the infection without losing 
the catheter. However, even after catheter removal, the 
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microbiological testing does not always demonstrate the 
micro-organism involved in the infectious process. Tradition-
ally, the diagnosis of CRB requires removal of the catheter 
in order to culture the 4 cms of the catheter tip.29 For ports, 
culture of the material inside the reservoir is more sensitive 
than catheter tip culture.30 When ports are removed, the 
silicone membrane is cut in order to open the reservoir, to 
vortex and culture the septum of the device using a quantita-
tive method.31 A cut-off of $103 CFU is used to differentiate 
significant from insignificant colonization.29 However, some 
micro-organisms, such as S. aureus, Candida species, or 
gram-negative bacilli, may have a lower CFU cut-off.
The quantitative method is based on flushing the catheter 
lumen with 2 mL of brain–heart infusion broth, which is 
diluted tenfold; 0.1 mL of each dilution is then streaked onto 
blood agar. The catheter lumen is considered significantly 
colonized if bacterial count is $103 CFU.11,32 The quantita-
tive catheter segment cultures have the highest sensitivity 
(80%–100%) and specificity (more than 90%), when com-
pared with semiquantitative or qualitative broth cultures, to 
diagnose CRB.33
The culture of the sonicated catheter has been shown to 
be useful in diagnosing CRB. This technique can recover 
micro-organisms from the external and the internal surface of 
the catheter. Sonication methods allow quantification of CFU 
removed from a catheter. A catheter culture in which $102 
CFU grow and has associated blood cultures in the previous 
48 hours is used to diagnose CRB.34
Semiquantitative roll-plate culture technique has been 
developed to assess the intraluminal and extraluminal 
colonization of the catheter. The semiquantitative method 
is performed rolling the catheter across the blood agar plate 
four times. The catheter tip is considered colonized, or it is 
suggestive of CRBSI, if the bacterial count is $15 CFU.9
Qualitative broth culture of port segments has high sensi-
tivity for microbiological diagnosis, but it cannot distinguish 
infection from contamination of the catheter. Often, a catheter 
is removed after antimicrobial treatment has begun. This situ-
ation could reduce the sensitivity of the cultures, leaving the 
diagnosis of CRI as presumptive.
Catheter-related bloodstream 
infection treatment
CRB is a major cause of patient morbidity, premature 
catheter removal, and increased treatment cost. When CRB 
is diagnosed, the most effective therapeutic strategy is to 
remove the device. Catheter retention is associated with a 
high risk of bacteremia recurrence.35 The catheter has to be 
removed if there are signs of subcutaneous tunnel infection, 
suppurative phlebitis, septic shock, peripheral or pulmonary 
embolization, clinical suggestion of infective endocarditis, 
persistent bacteremia, recurrent infection despite adequate 
medical treatment, or when the micro-organism involved 
is identified as S. aureus, Candida spp., or Mycobacterium 
spp.2 However, in many cases catheter removal is avoided as 
first step of treatment if the venous catheter was surgically 
implanted or may not be easily replaced, or if the patient is 
hemodynamically stable.36 In those cases, and according to 
the clinical guides, the use of the venous device is stopped, 
and local and systemic antibiotic treatment is initiated.2
Systemic antibiotic treatment
With uncomplicated CRBSI, if the catheter is removed, 
systemic antibiotic therapy is administered for up to 7 days. 
But if a tunnel infection or port abscess is diagnosed, it is 
necessary to remove the catheter, drain the tissue affected, and 
administer antibiotic treatment for 7 to 10 days, in the absence 
of concomitant bacteremia or fungemia.2 With purulent 
local complications, systemic antibiotic treatment without 
catheter removal has been demonstrated to be ineffective. 
In a series of 102 patients with hemodialysis catheters, 
Marr et al described treatment failure in 68% of cases of 
attempted catheter salvage. Most of these cases were related 
to gram-positive cocci infections, and the worst prognosis 
was associated with S. aureus serious complications.37 The 
choice of antimicrobial agent depends on microbiological 
isolates, but this is not always possible. For this reason, it is 
often necessary to start with empiric antibiotic treatment.38 
In this clinical scenario, the selection of the antimicrobial 
agent would consider not only the micro-organism involved, 
but the pharmacodynamics properties of the antimicrobial 
agent. It is a cautious measure to select a bactericidal over 
a bacteriostatic antimicrobial agent. To achieve therapeutic 
effectiveness, glycopeptides require maintaining AUC/MIC 
(area under the curve/minimum inhibitory concentration) 
during the dose interval. Beta-lactams require maintaining 
their concentration over the MIC during the dose interval.
Whenever the decision of maintaining the catheter in 
place has been made, empiric antibiotic therapy has to be 
administered intravenously and locally (antibiotic lock tech-
nique [ALT]) for 10 to 14 days. In cases of multiple-lumen 
catheters, the administration of antibiotics should rotate 
among different lumens.38 According to the IDSA guidelines, 
when the involved micro-organism is a CoNS or a gram-
negative bacilli, and there are positive blood cultures drawn 
from the catheter, but negative from peripheral vein, ALT 
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has to be considered from 10 to 14 days, without systemic 
antibiotic treatment.2
Antibiotic lock technique and clinical 
experience
Local antibiotic treatment, or ALT, was described for the first 
time in 1988 by Messing et al39 for treatment of CRB associ-
ated with parenteral nutrition. ALT consists of the  infusion of 
a concentrated antibiotic solution in a small volume to fill the 
lumen catheter. The rationality of this technique is to expose 
the interior walls of the catheter to high concentrations of 
an antibiotic that may penetrate the biofilm, and therefore 
to achieve bacterial eradication.  However, despite the efforts 
to conserve a highly needed venous catheter, the goal is not 
always reached, making the biofilm the principal source for 
chronic infections and the cause of catheter removal. It is 
important to note that even with microbiological diagnosis, 
the bacterial resistance profiles obtained in clinical laborato-
ries may not predict differences in the eradication effect of 
the antimicrobial agents in biofilms.40 At present, the selec-
tion of the most effective antimicrobial agent, the optimal 
antimicrobial concentration, and the best interval of time 
required for antibiotic lock solutions have yet to be defined. 
Antimicrobials agents that display postantibiotic effect, such 
as fluoroquinolones and aminoglycosides, may not require 
higher concentrations for antibiotic lock solutions, as glyco-
peptides or beta-lactams do.
Although ALT was described in 1988, the first random-
ized clinical trial had to wait until 2005, when Rijnders et al 
carried out a study to compare antibiotic lock treatment 
versus placebo in CRBSI.41 Despite having to stop the trial 
because of patient recruitment difficulties, their study showed 
that in patients with long-term intravenous device-related 
bloodstream infection, the use of an antibiotic lock solution 
in addition to parenterally administered antibiotics reduced 
the failure rate to cure the CRBSI from 57% to 33%. In this 
line, Fernandez-Hidalgo et al concluded in an open, non-
comparative study of 115 episodes of CRB in 98 patients 
that the combination of ALT with vancomycin 2,000 mg/L 
or ciprofloxacin 2,000 mg/L for gram-positive or -negative 
micro-organisms, respectively, with systemic antibiotics 
is effective to treat CRB, especially in gram-negative and 
CoNS CRB episodes.42 Their patients received a median of 
12 days of ALT and systemic treatment, and had an overall 
treatment success of 82%. They attributed their high cure rate 
to the fact that the catheter was not used during treatment 
but rather exposed to high antibiotic concentrations, and the 
concurrence of systemic antibiotic therapy.
Even though there are no randomized clinical trials that 
support them, glycopeptides are considered the drugs of 
choice for empiric treatment, as the incidence of methicillin 
resistance is high among CoNS, and there is a possibility of 
having an infection due to methicillin-resistant S. aureus, 
especially in medical health care environments. According to 
the experience of the authors of this review, ALT is a safe and 
effective treatment for port-related BSI when combined with 
systemic antibiotic therapy.43,44 Among the studied antibiotics, 
teicoplanin has shown better port survival rate compared to 
vancomycin when both were used for ALT.45 Del Pozo et al 
also evaluated the effectiveness of ALT in port-related BSI 
with micro-organisms different than CoNS. They reported 
that systemic treatment combined with ALT is effective and 
safe for treatment of port-related BSI, if patients are stable 
and have no septic syndrome.43
The efficacy of the antibiotic solution during this time is 
also a concern. Soriano et al carried out a clinical assay in 
patients with hemodialysis catheters. They determined the 
vancomycin concentration every 48 hours and reported that 
there exists a decreasing gradient of vancomycin concentra-
tion of almost 50%, from proximal to distal segments of 
subclavian and femoral hemodialysis catheters.46 Although 
the methodology of their assay may not necessarily reproduce 
the in vivo clinical situation of the antibiotic solution, their 
findings support the IDSA recommendation for replacing the 
antibiotic solution every 24 hours.2 It is necessary to eluci-
date the best time for antibiotic replacement with certainty 
of adequate concentration and antimicrobial activity with 
the passage of time.
One of the issues with ALT use is related to the high 
concentration of antibiotic used for the lock solution, and 
the possible side effects that may result from the solution 
passing into the bloodstream. Although there are few reports 
regarding this aspect, Elian et al reported that there was no 
significant change in the serum kinetics of vancomycin in 
two patients treated with systemic and ALT vancomycin.47 In 
a recent review focused on pharmacological stability of lock 
solutions, Morales-Molina et al found that the most studied 
solutions were those with vancomycin and ciprofloxacin. 
According to them, the best alternatives for antibiotic lock 
solution against gram-positive cocci, methicillin-resistant 
Staphylococcus aureus (MRSA) included, were vancomycin 
alone (2–10 mg/mL) or vancomycin (0.5–10 mg/mL) com-
bined with heparin (100–5,000 U/mL).48 Similar results in 
patients with hemodialysis catheters were experienced by 
Poole et al, using ALT combined with systemic antibiotic 
treatment. They observed an overall successful treatment of 
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70% of patients with CRB using ALT with vancomycin and 
ceftazidime, unless microbiological sensitivity had required 
modification of the antibiotic administered, for both local 
and systemic antibiotic treatment.49
Regarding treatment, using ALT with vancomycin, there 
is contradictory published information. Megged et al50 
described a series of 23 patients with an overall success 
rate of 30%. They observed that hemodialysis catheters had 
significantly higher salvage rates than ports (75% versus 
18%). In their study, all patients with an early or late relapse 
had a port. They attributed the difference in cure rate between 
catheters to variations in biofilm formation resulting from 
more complex structures within the ports, and the fact that 
they began ALT after 48 hours of bacteremia after appropriate 
systemic antimicrobial therapy had failed to treat the infec-
tion.50 Failure in treatment might be related to the virulence of 
the micro-organism involved in the infection. Several reports 
include S. aureus biofilm-related venous device infection with 
unsuccessful attempts of cure, and early decision of catheter 
removal due to the risk of serious complications, before trying 
to use the ALT.41,42 Maya et al conducted a prospective study, 
following 113 hemodialysis patients with S. aureus bacte-
remia trying to assess the outcome of patients treated with 
ALT. They reported clinical cure in almost 40% of patients 
treated with ALT and described 25% of serious complications 
in patients who experienced persistent fever.51
The search for different antibiotic options for CRBSI 
treatment continues. Del Pozo et al described 13 patients with 
long-term catheters (six ports and seven Hickman) treated 
with daptomycin lock therapy. All patients had gram-positive 
CRBSI. The authors described clinical cure and blood culture 
sterilization in 85% of the patients.44
The appropriate duration for ALT is another unresolved 
question. Evidence exists that treatment duration shorter than 
10–14 days might be enough for resolving biofilm-related 
venous catheter infections. A brief report of 3 days of ALT 
that resolved 81% of CRI was published in 2011.52 A previous 
report of 14 patients showed that a 3-day course of ALT asso-
ciated with 7 days of levofloxacin 500 mg achieved catheter 
salvage in 12 cases.53 In spite of reported data, the question 
is still open. It is necessary to obtain evidence through clini-
cal trials that may ensure that prolonging the antibiotic lock 
time inside the port is at least as effective and safe, for the 
patient, as current clinical guidelines.
Treatment failure criteria
Treatment failure is considered when the port has to be 
removed during local and systemic antimicrobial therapy, or 
after finishing antibiotic treatment due to persistence of fever 
(.72 hours after initiation of appropriate antibiotic therapy), 
or bacteremia (.72 hours) or venous access port culture with 
the same micro-organism after the end of the treatment.2
Prevention strategies for CRI
There are several published recommendations, based on 
clinical trials, to prevent CRI (Table 1). Some of them 
include simple and practical interventions that decrease the 
burden of venous catheter-related infections.54–56 It is man-
datory to perform hand hygiene before catheter insertion or 
manipulation. It is also imperative to disinfect catheter hubs, 
needleless connectors, and injection ports before accessing 
the catheter. For this purpose, preparations of alcoholic 
chlorhexidine and 70% alcohol are recommended.55,56 All 
successful preventive strategies incorporate three distinct 
methods to decrease CRI: diminish colonization of the 
catheter insertion site and hubs; minimizing the spread 
of micro-organisms from the skin to the catheter wall; 
and reducing microbial spread through the lumen catheter 
toward the bloodstream.54
The use of antibiotic prophylaxis at moment of catheter 
implantation to prevent CRB has always been questioned. In 
a survey performed in 2007, 606 members of the IDSA and 
the  Pediatric Infectious Disease Society were asked about the 
use of ALT and prophylaxis in their clinical practice. Only 
19% of the infectious diseases physicians reported using ALT 
prophylaxis. One hundred and fifty members reported using 
ALT to treat patients with CoNS CRBSI. Of them, 89% pre-
ferred vancomycin alone. Fifty-five members recommended a 
length of treatment of 10–14 days.57 Data from 1985 showed 
that prophylaxis with vancomycin at the time of catheter 
insertion did not reduce incidence of CRB.58 Other studies 
using vancomycin and teicoplanin were not able to rule out 
the possibility of a beneficial effect.54 Recently, a study com-
paring vancomycin and linezolid for prophylaxis of CRBSI 
in patients with temporary nontunneled hemodialysis cath-
eters showed no significant CRBSI incidence rate between 
both antibiotics; however, none of the patients locked with 
linezolid experienced CRBSI during the follow-up period.59 
There is also concern about inducing antibiotic resistance 
if bacterial cells are exposed to inadequate concentrations 
of antimicrobial agents. It is reasonable to try to avoid the 
use of antimicrobial therapeutic agents as pharmacological 
prevention of CRB. Moreover, IDSA recommends against the 
routine use of prophylactic antibiotic lock solutions.2,56 The 
use of ALT as prophylaxis for CRB has to be circumscribed to 
patients with limited venous access and a history of recurrent 
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central line-associated BSI, and to patients who are at higher 
risk for severe sequels from central line-associated BSI.55 
Recently, an open-labeled, randomized clinical trial showed 
noninferiority of normal saline compared with heparin to lock 
ports. CRBSI was 0.03 per 1,000 catheter days in the normal 
saline group and 0.10 per 1,000 catheter days in the heparin 
group.60 This data may support the use of no antimicrobial 
agents to prevent CRBSI.
Future directions
Diagnosing and treating CRBSI is a medical challenge. It 
is important to remember that simple and proven common-
sense measures such as hand washing, using full barrier 
precautions during CVC insertion, cleaning the skin with 
chlorhexidine, avoiding femoral catheter insertion, and 
removing unnecessary catheters have demonstrated a reduce 
in rates of CRBSI.61 New molecular technologies are avail-
able to obtain faster diagnosis of CRBSI, such as multiplex 
polymerase chain reaction (PCR) in blood cultures obtained 
from the ports. Promising innovations for patient care include 
the development of devices that prevent bacterial growth 
and biofilm development, new medical catheters with fibrin 
inhibitors, the use of functional antibodies against specific 
targets of micro-organisms, and the use of enzymes to break 
Table 1 Summary of some RCT and controlled studies’ published articles on catheter infection and prevention of CRBSI
Design N Intervention Main conclusion Reference
Retrospective 54 Oral prophylaxis with doxycycline in HCT patients No CvC infection in the doxycycline group 62
Retrospective 459 Single dose of antibiotic during placement of TIvPAs Decrease of CRI 63
Observational 179 Perioperative prophylactic cefuroxime administration No CRBSI reported 64
Crossover,  
randomized
26 Oral prophylaxis with novobiocin and rifampin effectiveness of antibiotic prophylaxis 65
Randomized 40 3 days of vancomycin during insertion of CvC Bacteremic episodes reduced  
in the vancomycin group
66
Randomized,  
controlled
148 Amoxicillin prophylaxis to prevent CRI Failure to demonstrate benefit  
of amoxicillin prophylaxis
67
Randomized 88 Teicoplanin before insertion of Hickman catheter Lower incidence of CRS in teicoplanin arm 68
Randomized,  
controlled
98 vancomycin during placement of long-term CvC Failure to reduce CRS 69
Randomized 47 Single dose of vancomycin at time of insertion of CvC Failure to reduce CRS 70
Ethanol lock technique
Retrospective 31 70% ethanol lock solution followed by NaCl 0.9% flushing Reduced CRBSI-related admissions 71
Randomized,  
double-blind
376 70% ethanol vs placebo for 15 minutes followed  
by NaCl 0.9% flushing
No significant difference between groups 72
Prospective,  
open-label
12 Overnight 70% ethanol lock solution No significant difference observed 73
Antiseptic-impregnated and antibiotic-impregnated catheters
Randomized 133 Chlorhexidine and silver sulfadiazine catheters vs  
nonimpregnated
Failure to reduce incidence  
of colonization or CRBSI
74
Randomized 204 Chlorhexidine and silver sulfadiazine catheter vs  
no antiseptic catheter
No significant difference between groups 75
Randomized,  
double-blind
370 Minocycline and rifampin catheters vs no antimicrobial  
catheters
Antimicrobial catheters decreased CRI 76
Randomized 228 Chlorhexidine and silver sulfadiazine catheters vs  
no antiseptic catheters
Antiseptic-bonded catheters have  
lower colonization rate
77
Randomized 817 Chlorhexidine and sulfadiazine vs minocycline  
and rifampin catheters
Antibiotic catheters had lower  
colonization and CRBSI
78
Randomized,  
controlled
119 Chlorhexidine and sulfadiazine catheters vs  
nonimpregnated
Reduction of colonization  
in the antibiotic arm
79
Randomized,  
double-blind
538 Chlorhexidine and silver sulfadiazine catheters vs  
nonimpregnated
No significant difference between groups 80
Randomized,  
controlled
158 Chlorhexidine and silver sulfadiazine catheters vs  
nonimpregnated
Reduced incidence of CRI 81
Randomized,  
double-blind
281 Coated minocycline and rifampin CvC Antibiotic-coated CvC reduced  
colonization and BSI
82
Randomized 233 Chlorhexidine and sulfadiazine catheters vs  
nonimpregnated
Reduction of colonization  
in the antibiotic group
83
Randomized 20 Teicoplanin-coated CvC vs noncoated antibiotic CvC No significant difference between groups 84
Abbreviations: BSI, bloodstream infection; CRBSI, catheter-related bloodstream infection; CRI, catheter-related infection; CRS, catheter-related sepsis; CvC, central 
venous catheter; HCT, hematopoietic cell transplantation; RCT, randomized controlled trial; TIvPA, totally implanted venous port access; vs, versus.
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down the biofilm integrity or to modify protein expression of 
bacterial cells within the biofilm. At present, there are still 
gaps to be filled, such as the best antimicrobial agent to treat 
CRBSI, and the period of time that an antibiotic solution may 
remain inside the lumen of the port without losing antimicro-
bial activity. It is necessary to improve our knowledge and 
practice of actual medical care through randomized clinical 
trials in order to overcome biofilm-related infections.
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